Editas Medicine Inc expected to post a loss of 78 cents a share - Earnings Preview

Editas Medicine

28/04/2023 19:27

* Editas Medicine Inc  EDIT.OQ   EDIT.O  is expected to show
a
fall in quarterly revenue when it reports  results on May 2
(estimated). 
    * The Cambridge Massachusetts-based  company is expected to
report
 a 55.6% decrease in revenue to $3.008 million from $6.77
million a year ago, according to the mean estimate from 12
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Editas Medicine Inc
is
for a loss of 78 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 11
"hold" and 3 "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 0.6%
in the last three months. ​
    * Wall Street's median 12-month price target for Editas
Medicine
Inc is $12​, above​ its last closing price of $8.02. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.80       -0.80      -0.88     Missed  -9.7
 Sep. 30 2022  -0.83       -0.87      -0.81     Beat    6.8
 Jun. 30 2022  -0.81       -0.82      -0.78     Beat    5.1​
 Mar. 31 2022  -0.78       -0.80      -0.74     Beat    6.9
 ​​Dec.        -0.68       -0.72      -0.61     Beat    15.4
 31 2021                                                
 Sep. 30 2021  -0.83       -0.82      -0.57     Beat    30.2​
 Jun. 30 2021  -0.84       -0.83      -0.81     Beat    2.1
 Mar. 31 2021  -0.74       -0.73      -0.86     Missed  -17.1
 This summary was machine generated April 28 at 18:27 GMT.  All
figures in US dollars  unless otherwise stated